Compared to traditional treatments like metronidazole and vancomycin, fidaxomicin has been shown to have a lower rate of recurrence for C. difficile infections. This is particularly important as recurrent infections are a major challenge in the management of C. difficile. Additionally, fidaxomicin's targeted mechanism reduces the likelihood of developing resistance compared to broad-spectrum antibiotics.
